Protein yippee-like 2 (YPEL2)

Protein yippee-like 2 (YPEL2) is a member of the highly conserved YPEL gene family, with high sequence homology across species from yeast to humans[1][2][3]. Predicted to bind metal ions and localized to the nucleolus, YPEL2 is not classified as a classic therapeutic target such as a receptor, enzyme, or ion channel[2][4]. It is involved in a range of fundamental cellular processes, including cell proliferation, differentiation, senescence (especially via p53/p21 pathway), and death, as well as RNA processing, ribosome biogenesis, and stress granule formation[1][2][3]. YPEL2 is notably expressed in vascular-rich tissues (heart, kidney, lung) and is implicated in vascular senescence and atherosclerosis[2]. Genomic studies associate YPEL2's locus with susceptibility to retinitis pigmentosa, developmental dysplasia of the hip, and possibly regulation of HIV-1 reservoir levels[2][4]. Overexpression in cell models leads to cellular and nuclear disruption and rapid cell death[1]. There are currently no known drugs directly targeting YPEL2, and its direct application in therapeutics or as a clinical biomarker has not been established.

Other names

FKSG4DiGeorge syndrome-related proteinprotein yippee-like 2